[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2017

December 2017 | 116 pages | ID: UE31895F937EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Chemotherapy Induced Peripheral Neuropathy Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Chemotherapy Induced Peripheral Neuropathy Treatment in these regions, from 2012 to 2022 (forecast).
United States Chemotherapy Induced Peripheral Neuropathy Treatment market competition by top manufacturers/players, with Chemotherapy Induced Peripheral Neuropathy Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Achelios Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Apollo Endosurgery Inc
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Can-Fite BioPharma Ltd
  • Celgene Corp
  • DermaXon LLC
  • Eisai
  • Immune Pharmaceuticals Inc
  • INSYS Therapeutics Inc
  • Kineta Inc
  • KPI Therapeutics Inc
  • Krenitsky Pharmaceuticals Inc
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Midatech Pharma US Inc
  • Mundipharma International Ltd
  • Nemus Bioscience Inc
  • Neurocentrx Pharma Ltd
  • Panacea Pharmaceuticals Inc
  • PeriphaGen Inc
  • PharmatrophiX Inc
  • PledPharma AB
  • Sova Pharmaceuticals Inc
  • Virobay Inc
  • WEX Pharmaceuticals Inc
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • APX-3330
  • BR-297
  • Cannabidiol
  • Dimiracetam
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Clinic
  • Hospital
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2017

1 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT OVERVIEW

1.1 Product Overview and Scope of Chemotherapy Induced Peripheral Neuropathy Treatment
1.2 Classification of Chemotherapy Induced Peripheral Neuropathy Treatment by Product Category
  1.2.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 APX-3330
  1.2.4 BR-297
  1.2.5 Cannabidiol
  1.2.6 Dimiracetam
  1.2.7 Others
1.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application/End Users
  1.3.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market by Region
  1.4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
  1.4.3 Southwest Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
  1.4.5 New England Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
  1.4.6 The South Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
  1.4.7 The Midwest Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Chemotherapy Induced Peripheral Neuropathy Treatment (2012-2022)
  1.5.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2012-2022)
  1.5.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2012-2022)

2 UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Players/Suppliers (2012-2017)
2.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
  2.4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate
  2.4.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Region (2012-2017)
3.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Region (2012-2017)
3.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Price by Region (2012-2017)

4 UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2012-2017)
4.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2012-2017)
4.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Type (2012-2017)

5 UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Application (2012-2017)
5.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Achelios Therapeutics Inc
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Advinus Therapeutics Ltd
  6.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Apollo Endosurgery Inc
  6.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Aptinyx Inc
  6.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Asahi Kasei Pharma Corp
  6.5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Can-Fite BioPharma Ltd
  6.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Celgene Corp
  6.7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 DermaXon LLC
  6.8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Eisai
  6.9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Immune Pharmaceuticals Inc
  6.10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 INSYS Therapeutics Inc
6.12 Kineta Inc
6.13 KPI Therapeutics Inc
6.14 Krenitsky Pharmaceuticals Inc
6.15 MAKScientific LLC
6.16 Metys Pharmaceuticals AG
6.17 Midatech Pharma US Inc
6.18 Mundipharma International Ltd
6.19 Nemus Bioscience Inc
6.20 Neurocentrx Pharma Ltd
6.21 Panacea Pharmaceuticals Inc
6.22 PeriphaGen Inc
6.23 PharmatrophiX Inc
6.24 PledPharma AB
6.25 Sova Pharmaceuticals Inc
6.26 Virobay Inc
6.27 WEX Pharmaceuticals Inc

7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MANUFACTURING COST ANALYSIS

7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Chemotherapy Induced Peripheral Neuropathy Treatment Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Forecast by Type (2017-2022)
11.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Forecast by Application (2017-2022)
11.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (K Pcs) by Type (2012-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Market Share by Type (Product Category) in 2016
Figure APX-3330 Product Picture
Figure BR-297 Product Picture
Figure Cannabidiol Product Picture
Figure Dimiracetam Product Picture
Figure Others Product Picture
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2016
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Million USD) by Region (2012-2022)
Figure The West Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Players/Suppliers
Figure 2017 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Players/Suppliers
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players/Suppliers
Figure 2017 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players/Suppliers
Table United States Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Share of Top 3 Players/Suppliers
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Chemotherapy Induced Peripheral Neuropathy Treatment Product Category
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs) by Region (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Region (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Region (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2016
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Region (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in 2016
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Pcs) by Region (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs) by Type (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2016
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2012-2017)
Figure Revenue Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2016
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Pcs) by Types (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Type (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs) by Application (2012-2017)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2016
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2012-2017)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2012-2017)
Table Achelios Therapeutics Inc Basic Information List
Table Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Advinus Therapeutics Ltd Basic Information List
Table Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Apollo Endosurgery Inc Basic Information List
Table Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Aptinyx Inc Basic Information List
Table Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Asahi Kasei Pharma Corp Basic Information List
Table Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Can-Fite BioPharma Ltd Basic Information List
Table Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Celgene Corp Basic Information List
Table Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table DermaXon LLC Basic Information List
Table DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Eisai Basic Information List
Table Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table Immune Pharmaceuticals Inc Basic Information List
Table Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2012-2017)
Figure Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in United States (2012-2017)
Figure Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in United States (2012-2017)
Table INSYS Therapeutics Inc Basic Information List
Table Kineta Inc Basic Information List
Table KPI Therapeutics Inc Basic Information List
Table Krenitsky Pharmaceuticals Inc Basic Information List
Table MAKScientific LLC Basic Information List
Table Metys Pharmaceuticals AG Basic Information List
Table Midatech Pharma US Inc Basic Information List
Table Mundipharma International Ltd Basic Information List
Table Nemus Bioscience Inc Basic Information List
Table Neurocentrx Pharma Ltd Basic Information List
Table Panacea Pharmaceuticals Inc Basic Information List
Table PeriphaGen Inc Basic Information List
Table PharmatrophiX Inc Basic Information List
Table PledPharma AB Basic Information List
Table Sova Pharmaceuticals Inc Basic Information List
Table Virobay Inc Basic Information List
Table WEX Pharmaceuticals Inc Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
Table Raw Materials Sources of Chemotherapy Induced Peripheral Neuropathy Treatment Major Players/Suppliers in 2016
Table Major Buyers of Chemotherapy Induced Peripheral Neuropathy Treatment
Table Distributors/Traders List
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories